| abstract |
What is described is an aqueous pharmaceutical formulation for intranasal delivery of liraglutide, comprising liraglutide, a solubilizing agent, and a chelating agent; a dosage form comprising the formulation; and a method of using such formulation for treating metabolic diseases in a mammal. Also described is a method for treating metabolic diseases in a mammal comprising administering intranasally a liraglutide formulation comprises a therapeutically effective amount of liraglutide and one or more excipients selected from the group consisting of a solubilizing agent and a chelating agent. |